The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 Dyes Offer Precise Excitation and Emission Spectra for Improved Brightness and Resolution
HERCULES, Calif. —Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today introduced three StarBright Dyes designed for flow cytometry applications.
StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 Dyes offer improved brightness and precise excitation and emission spectra, making them suitable for use in multicolor flow cytometry panels. Bio-Rad’s line of StarBright Dyes offers researchers a range of fluorescent nanoparticles conjugated to highly validated flow antibodies.
"The new StarBright Dyes offer improved brightness when compared to other available dyes at similar wavelengths, and they may be used with a wide range of flow cytometers," said Mike Blundell, PhD, Bio-Rad Product Manager, Flow Cytometry, Life Science Group. "The unique profile of the dyes offers enhanced resolution of rare populations and low-density antigens as well as consistent and reproducible staining."
Key Benefits of StarBright Dyes
- Compatible with new and existing protocols and suitable for use in multiplex panels
- Resistant to photobleaching and highly stable with minimal lot-to-lot variation
- Offer reliable Förster resonance energy transfer (FRET) for reproducible data
- Work with common staining buffers, including special polymer dye staining buffers, for easy integration into multicolor panels
- Ensure no loss of signal in fixation
- Offer narrow excitation and emission profiles for improved resolution in new and existing multicolor flow cytometry experiments
The StarBright Dyes are compatible with Bio-Rad’s ZE5 Cell Analyzer, S3e Cell Sorter, and other conventional and spectral flow cytometers.
Please visit www.bio-rad-antibodies.com/starbright for more information about the StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 Dyes.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements
Media Contact:
Bio-Rad Laboratories, Inc.
Nico Tuason, Sr. Marketing Manager
510-368-0203
nico_tuason@bio-rad.com
Zyme Communications
Dr. Michelle Ricketts
+44 (0)778 9053 885
michelle.ricketts@zymecommunications.com